Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.

Pharmaceutical 197

Pharmaceutical 197

MedCity News

OCTOBER 28, 2024

Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson. The post AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition appeared first on MedCity News.

Prospecting 88

Prospecting Biopharma Pharma 88

Fierce Pharma

OCTOBER 28, 2024

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.&nb | While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

Medicine 180

Medicine Marketing Patients 180

MedCity News

OCTOBER 28, 2024

HealthJoy and Mark Cuban Cost Plus Drug Company have teamed up. Through the partnership, HealthJoy can now direct the employees of its clients to the drug company when it offers a cheaper option for generic drugs. The post HealthJoy, Cost Plus Drugs Partner To Reduce Drug Costs for Employers appeared first on MedCity News.

82

82

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Fierce Pharma

OCTOBER 28, 2024

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this yea

Leads 166

Leads Pharmaceutical 166

MedCity News

OCTOBER 28, 2024

Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer. The post Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications appeared first on MedCity News.

Pharma 70

Pharma Biopharma 70

MedCity News

OCTOBER 28, 2024

To fully capitalize on its potential, laboratories must ensure they understand how to use AI effectively. Without this understanding, there’s a risk of undermining the technology’s benefits and potentially harming the industry as a whole. The post Harnessing AI in Pathology: A Vital Tool That Requires Careful Ownership appeared first on MedCity News.

67

67

pharmaphorum

OCTOBER 28, 2024

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies for the disorder.Data reported at the Kidney Week 2024 congress in San Diego showed that felzartamab was able to achieve "substantial" reductions in proteinuria and stabilised kidney function in the 54-subject IGNAZ study that extended for 18 months after the last dose of the antibody.

67

67

MedCity News

OCTOBER 28, 2024

Clearinghouses are just one great example of how the enhanced exchange of healthcare data can increase efficiency for healthcare providers and the greater healthcare community. The post Increasing Efficiency and Reimbursements with Clearinghouses appeared first on MedCity News.

Healthcare Provider 64

Healthcare Provider Healthcare Healthcare 64

European Pharmaceutical Review

OCTOBER 28, 2024

Phase III findings showed that TREMFYA ® (guselkumab) is the first IL-23 inhibitor to demonstrate results in subcutaneous induction and maintenance therapy of Crohn’s disease. New Phase III data from Johnson & Johnson has shown that the biologic could become the first IL-23 treatment to offer both a subcutaneous and intravenous induction regimen for the autoimmune condition.

Medicine 59

Medicine Patients Management Leads 59

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

pharmaphorum

OCTOBER 28, 2024

Novartis says Fabhalta shows sustained efficacy in rare disease C3G over 12 months, as it prepares for an FDA filing later this year

FDA 70

FDA 70

ALULA

OCTOBER 28, 2024

Wasn’t AI supposed to make our working lives easier? A recent survey by Upwork Inc., one of the world’s biggest online freelance worker marketplaces, found that while 96% of C-Suite leaders said they expected AI to boost productivity, 77% of employees reported that AI had “added to their workload” and half said “they have no idea how to achieve the productivity gains their employers expect.

52

52

PharmExec

OCTOBER 28, 2024

Collaboration seeks to advance the treatment of non-small cell lung cancer by combining Keytruda with Moderna’s novel neoantigen therapy, which has shown positive results across cancer types.

52

52

Pharmaceutical Technology

OCTOBER 28, 2024

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 is a strategic platform for discussion and collaboration among decision makers, researchers and technologists who understand and follow this tendency.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

PharmExec

OCTOBER 28, 2024

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explain how the regulatory framework for compounded medications can be further strengthened to ensure quality and safety, while still maintaining flexibility to address patient needs.

Medical 52

Medical Safety Patients 52

Pharmaceutical Technology

OCTOBER 28, 2024

The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the well-being of marginalised communities affected by this practice today.

52

52

pharmaphorum

OCTOBER 28, 2024

MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.

67

67

PharmaTech

OCTOBER 28, 2024

Emerging therapies, patient-centric medicines, and the ever-changing world of bio/pharmaceuticals complicate technology transfer.

Medicine 59

Medicine Pharmaceutical Patients 59

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales

pharmaphorum

OCTOBER 28, 2024

Astellas confirmed today it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy in the EU

57

57

Pharmaceutical Commerce

OCTOBER 28, 2024

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Consulting 52

Consulting Healthcare Healthcare 52

PharmaVoice

OCTOBER 28, 2024

As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.

52

52

Pharmaceutical Commerce

OCTOBER 28, 2024

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

Media 59

Media Biopharma 59

Advertisement

Distribution

PharmExec

OCTOBER 28, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmaceutical Technology

OCTOBER 28, 2024

At the Outsourcing in Clinical Trials conference, Rohan Simon from the UAE CRO IROS, spoke about the region’s clinical trials landscape.

52

52

PharmExec

OCTOBER 28, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52

Pharma 52

Pharmaceutical Technology

OCTOBER 28, 2024

Motivated patients with rare diseases are using social media widely, making it an effective way to reach patients for trial recruitment.

Media 52

Media Recruitment Patients 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmExec

OCTOBER 28, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmaceutical Technology

OCTOBER 28, 2024

Ahead of the upcoming DSCSA November deadline, pharma companies reimagine track-and-trace to tackle the US counterfeit drug landscape.

Pharma 52

Pharma 52

Pharmaceutical Commerce

OCTOBER 28, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 52

Distribution Biopharma Marketing 52

Pharmaceutical Technology

OCTOBER 28, 2024

China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western countries.

Medicine 52

Medicine Manufacturing 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution